Cover Image

In vivo evaluation of anticancer activity of novel 6-fluoro-3-(piperidin-4-yl) benzo[d]isoxazole derivatives against ehrlich ascites carcinoma in mice

Sharath Chandra S.P.*, Periyapatna Vishwaprakash Mahadimane


The aim of the present study is to investigate the anticancer properties of newly synthesized benzisoxazole derivatives (S1-S4) in Swiss albino mice against Ehrlich Ascites Carcinoma (EAC) cell line. The anticancer activity of synthesized molecules and 5 fluorouracil was investigated against Ehrlich ascites carcinoma (EAC) tumor in mice at dose of 20 mg/kg body weight (orally and intra peritoneally). Acute oral toxicity studies were performed to ensure the safety of the molecules. EAC cells were injected (i.p.) into ninety six mice (divided into 6 equal groups), and after a one-day incubation period, both molecules and drug was administered to the mice daily for 14 days. On day 15, 6 animals in each group were sacrificed for observation of anticancer activity like mean increase in body weight and viability of cancer cells. Whereas mean survival rate and percentage of increase in life span was conducted for a period of 6 weeks. Administration of the synthesized molecules resulted in a significant (p < 0.05) decrease in tumor volume and viable cell count, and increased non-viable cell count and mean survival time, resulting in increase of the life span of the EAC-bearing mice. The results indicate that the synthesized molecules (S2 and S3) exhibited significant anticancer activity comparable to that of standard drug 5 fluorouracil.


Anticancer; Benzisoxazole; EAC; Viable cells; Tumor volume

Full Text:



Atta-ur-Rahman, SR Angle JG. Breitenbucher (Eds), Sereoselective Synthesis, Elesvier, New York. 1995, 453-502.

Mokio G, AT Soldatenkov, VO Federov, EA Ageev, ND. Sergeeva, S Lin, E Stashenku, NS Prostakov, EL Andreeva, Khim. Farm. Zh. 1989, 23, 421.

Richards GJ, BC Juan, RA Macio, M Roldan, CR Peinado, Fernan-do, Spen. 1979, 47-168.

Hagenbach RE, H Gysin, Experimentia. 1952, 8, 184.

Dimmock JR & Kumar P. 1997, Curr. Med. Chem. 4, 1–22.

Kubota HA, Kakefuda Y, Okamoto M Fujii, O Yamamoto, Y Yamgiwa, M Orita K, Ikeda M, Takenchi Y Fsomura, Chem. Pharm. Bull. 1998, 46, 1538.

Priya BS, Basappa, Swamy SN, Rangappa KS. Bioorg. Med. Chem. 2005, 13, 2623‐2628.

Gopalsamy A, Shi M, Golas J, Vogan E, Jacob J, Johnson M, Lee F, Nilakantan R, Petersen R, Svenson K, Chopra R, Tam MS, WenY, Ellingboe J, Arndt K, Boschelli F. J. Med. Chem. 2008, 51, 373‐379.

Jain M, Kwon CH. J. Med. Chem. 2003, 46, 5428‐5434.

Davis L, Effland RC, Klein JT, Dunn RW, Geyer HM, Petko WM. Drug Design Disc. 1992, 8, 225‐240.

Strupczewski JT, Allen RC, Gardner BA, Schmid BL, Stache U, Glamkowski EJ, Jones MC, Ellis DB, Huger FP, Dunn RW. J. Med. Chem. 1985, 28, 761‐767.

Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TFJ. Pharmacol. Exp. Ther. 1988, 244, 685‐691.

Sharath Chandra SP, Raghava B, Sharada AC. Synthesis, Characterisation, Molecular property prediction and Antipsychotic activity of Novel 6-fluoro -3- (piperidin-4-yl) benzo [d] isoxazole Derivatives. International Journal of Pharmaceutical Sciences Review and Research, eISSN: 0976-044X (in press).

Segura JA, LG Barero and J Marquez. Ehrlich ascites tumor unbalances splenic cell populations and reduced responsiveness of T- cells to Staphylococcus aureus enterotoxin B stimulation. Immunomol. Lett 2000; 74: 111-15.

Price VE, Greenfield RE. Anemia in cancer, In: Greenstein JP, Haddow A, Eds. Advances in Cancer Research; Vol 5. New York: Academic Press; 1958. p 199-200.

Prasad SB, Giri A. Antitumor effect of cisplatin against murine ascites ascites Dalton’s lymphoma. Indian J Expt Biol. 1994; 32:155– 162.

Jesmin M, Ali MM, Biswas MK, et al. Antineoplastic Activity of Nickel (II) Cystine Complex against Ehrlich Ascites Carcinoma in Swiss Albino Mice. Med J Isl W Acad Sci (Turkey) 2007; 16:135-142.

Clarkson BD, Buirchenal JH. Preleminary screening of antineoplastic drugs. Prog Clin Cancer 1965; 1: 625-629.

Bhist M, Bist SS, Dhasmana DC. Biological response modifiers: Current use and future prospects in cancer therapy. Indian Journal of Cancer 2010; 47(4): 443-451.



  • There are currently no refbacks.

Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.